Gabitril
Product Images NDC 68151-4235

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabitril (NDC 68151-4235). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

63459040430

GABITRIL tablet imprints include a score line with an unclear character on one side and the numbers '404' on the other. The round, pale yellow tablet measures approximately 7 to 12 mm in diameter. No active ingredient or strength is visible. Labeler is Carilion Materials Management with NDC 68151-4235.*

FDA Label Image

Structure (Image 01)

Chemical structure of the active ingredient in GABITRIL, depicting its molecular formula with specific atoms, bonds, and functional groups including a piperidine ring and two methylthiophene rings, along with an HCl molecule indicating the hydrochloride form.*

FDA Label Image

Figure01 (Image 02)

A line graph comparing the percentage reduction in partial seizure rate for GABITRIL 32 + 56 mg/day versus placebo. The y-axis represents percent reduction in partial seizure rate, with improvement and worsening directions indicated. The x-axis shows the percentage of patients. The solid line represents GABITRIL treatment, and the dotted line represents placebo.*

FDA Label Image

Figure02 (Image 03)

A cumulative distribution plot showing the percentage reduction in partial seizure rate versus percentage of patients for GABITRIL at doses of 16 mg/day, 32 mg/day, 56 mg/day, and placebo. The y-axis represents percent reduction, with improvement and worsening indicated, while the x-axis shows the percentage of patients.*

FDA Label Image

Figure03 (Image 04)

A line chart showing the percentage reduction in partial seizure rate versus the percentage of patients. It compares three groups: Placebo, GABITRIL 8 mg QID, and GABITRIL 16 mg BID. The vertical axis indicates improvement and worsening of seizure rates, with statistical curves for each treatment group.*

FDA Label Image

Figure04 (Image 05)

A line graph comparing the percent reduction in partial seizure rate between a placebo group and patients treated with GABITRIL 10 mg TID. The x-axis represents the percentage of patients, and the y-axis shows percent reduction in partial seizure rate, with labels indicating improvement, no change, and worsening.*

FDA Label Image

Tevalogo.jpg (Image 10)

FDA Label Image

Label Image (Lbl681514235)

Label for GABITRIL 4 mg tablets, containing the active ingredient tiagabine hydrochloride. The label indicates the manufacturer as Cephalon, lists lot number GB30312, expiry date 07/14, and includes a barcode with the number 0000004235. It is marked RX only and for prescription use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.